Tailoring Radiotherapy to Each Patient's Response in Several Cancers
Tests adapting radiation treatment to individual responses in adults with several cancers.
Plain-language title generated from the registry record
Registry title: Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Key facts
- Where
- Dallas, United StatesSee the site
- Phase
- Phase 1
Where in United States
- UT Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT07139990
- Record updated
- 17 August 2026
- Original description
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.Read full original descriptionShow less
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM): A Multi-cohort Platform Trial of Adaptive Radiotherapy Approaches in Multiple Cancer Types
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
Inclusion: Cohort A:; >=18 years old; Performance status ECOG 0-2; Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration; Patient must be planned for or receiving standard of care chemoimmunotherapy; Patient must have received no more than 3 cycles by time of study enrollment; Able and indicated according to investigator to receive thoracic radiotherapy; Cohort B:; 18 years old; Diagnosis of solid tumor malignancy with MRI-defined brain metastasis lesions within 60 days of registration; Each brain metastasis lesion enrolled must be 2 - 5 cm, except brainstem lesions which may be 1.5 - 5cm in size; Cohort C:; >=18 years old; Performance status ECOG 0-2; Histologically confirmed surgically resectable, high grade (FNCLCC grade 2 or 3), localized soft tissue sarcoma of the trunk or extremities that measures >5 cm in any direction as assessed by imaging; Eligible to receive immunotherapy; Cohort D:; >=18 years old; Performance status ECOG 0-2; Pathologically proven diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx; Clinical stage III/IVA (AJCC 8th edition); Disease must be deemed resectable by head and neck surgeon; Eligible to receive immunotherapy.
Exclusion: ⨀ Prior thoracic Radiotherapy; Prior whole brain Radiotherapy; Prior surgical resection or focal radiotherapy of a target brain metastasis; Prior immunotherapy; Prior systemic chemotherapy for the study cancer; prior chemotherapy for a remote cancer is allowable; Prior immunotherapy for the study cancer or for a remote cancer; Prior head and neck radiotherapy; Leptomeningeal disease; Cohort C:; Unresectable or metastatic (nodal or distant) disease; Synchronous malignancy requiring chemotherapy or other intensive treatment; HPV-positive or p16-positive oropharyngeal cancer; Cohort A:; Cohort B:; Locally recurrent soft tissue sarcoma; Pregnancy or breastfeeding; Cohort D:; Distant metastasis; Inability to undergo PET-CT for baseline staging.